STAA:NSD-STAAR Surgical Company (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 29.49

Change

-0.80 (-2.64)%

Market Cap

USD 1.51B

Volume

0.81M

Analyst Target

USD 64.60
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

-2.54 (-0.49%)

USD 182.57B
COO The Cooper Companies, Inc. Com..

+0.67 (+0.64%)

USD 21.47B
HOLX Hologic Inc

+0.32 (+0.40%)

USD 18.90B
ALGN Align Technology Inc

-1.92 (-0.90%)

USD 15.89B
RGEN Repligen Corporation

+1.51 (+1.12%)

USD 8.01B
MMSI Merit Medical Systems Inc

-1.00 (-1.04%)

USD 5.55B
XRAY Dentsply Sirona Inc

+0.18 (+0.77%)

USD 4.87B
ICUI ICU Medical Inc

+0.37 (+0.21%)

USD 4.34B
AZTA Azenta Inc

+0.32 (+0.77%)

USD 2.04B
LMAT LeMaitre Vascular Inc

-1.36 (-1.50%)

USD 1.96B

ETFs Containing STAA

XMLH:XETRA L&G Healthcare Breakthrou.. 1.92 % 0.00 %

+0.06 (+0.62%)

USD 0.07B
XMLH:F Legal & General Ucits Etf.. 1.92 % 0.00 %

N/A

USD 0.07B
DOCT:SW L&G Healthcare Breakthrou.. 1.92 % 0.00 %

+0.06 (+0.62%)

USD 0.06B
XSU:CA iShares US Small Cap (CAD.. 0.00 % 0.36 %

N/A

CAD 0.75B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.51% 52% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.51% 52% F 40% F
Trailing 12 Months  
Capital Gain -31.93% 28% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.93% 28% F 21% F
Trailing 5 Years  
Capital Gain -11.39% 52% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.39% 52% F 44% F
Average Annual (5 Year Horizon)  
Capital Gain 22.57% 70% C- 77% C+
Dividend Return 22.57% 70% C- 76% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 94.33% 26% F 22% F
Risk Adjusted Return 23.92% 65% D 57% F
Market Capitalization 1.51B 74% C 76% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.